ClinicalTrials.gg
Active, not recruitingNCT05548582Updated Jan 12, 2026

Reduced Opioid Prescription After Laparoscopic Hysterectomy

An interventional study of OxyCODONE 5 mg Oral Tablet and Acetaminophen 500 mg Tab in Pain, Postoperative, Opioid Misuse and Opioid Use, sponsored by Johns Hopkins University. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Johns Hopkins University · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies testing oxycodone in Pain, Postoperative — 5 open to participants now, 7 under way, 1 of them phase 3. Oxycodone · Pain, Postoperative.

Planned enrollment
17th of 32
120 · median 126
Started
2023
with 1 other
No phase
6 of 32
2 open now
Registered
25th of 32
by date

Among the 32 studies testing oxycodone in Pain, Postoperative, this one is the 17th largest by planned enrollment, is one of 2 that started in 2023, is one of 6 with no phase, and was the 25th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

5 of the 32 studies testing oxycodone in Pain, Postoperative are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About oxycodone

Oxycodone: first FDA approval 1950 (PERCODAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing oxycodone in Pain, Postoperative, or all of them as a file.
02

Study summary

Given the nationwide epidemic of opioid use and abuse (in part due to over prescription), this study aims at addressing the need for opioid prescription after laparoscopic hysterectomy.

Read the detailed description

Currently, there is a nationwide epidemic of opioid abuse and overdose deaths. One source of excess opioids is overprescribing in the postoperative period. Given the increasing opioid abuse and over-prescription post-operatively, an effort must be made to determine whether non-opioid multimodal medications are adequate in treating postoperative pain after laparoscopic hysterectomy and would not increase the need for additional prescriptions or unscheduled patient contacts. This study aims to find the optimal prescriptions for pain after laparoscopic hysterectomy in an attempt to eliminate opioid use.

03

Conditions studied

  • Pain, Postoperative
  • Opioid Misuse
  • Opioid Use
  • Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over the age of 18 undergoing outpatient laparoscopic (conventional or robotic) hysterectomy for benign indications

Exclusion criteria

Exclusion Criteria:

  • Allergy or other to the prescribed medications such as acetaminophen, ibuprofen, or oxycodone
  • Known opioid use or abuse (defined as reported use or treatment for abuse within the last 3 months)
  • Chronic pain patients
  • Conversion to laparotomy
  • as the indication for surgery
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Other
    Post-operative opioid prescription

    Ibuprofen 600mg every 6 hours x 48 hours then as needed (total 30 tablets). If allergy or contraindication to ibuprofen, then will receive Meloxicam 15mg daily x 48 hours then as needed Acetaminophen 500mg every 6 hours x 48 hours then as needed (total 30 tablets) Oxycodone 5mg every 4 hours as needed (total 12 tablets)

    Drug: OxyCODONE 5 mg Oral Tablet · Drug: Acetaminophen 500 mg Tab · Drug: Ibuprofen 600 mg

  • Active comparator
    No Opioid prescription

    Ibuprofen 600mg every 6 hours x 48 hours then as needed (total 30 tablets). If allergy or contraindication to ibuprofen, will receive Meloxicam 15mg daily x 48 hours then as needed Acetaminophen 500mg every 6 hours x 48 hours then as needed (total 30 tablets)

    Drug: Acetaminophen 500 mg Tab · Drug: Ibuprofen 600 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Pain score on post-operative day one

    Numeric pain score on post-operative day one: patient reported pain using the Likert pain scale from 0 to 10

    Time frame: 1 day

  2. Pain score on post-operative day seven

    Numeric pain score on post-operative day seven: patient reported pain using the Likert pain scale from 0 to 10

    Time frame: 7 days

Secondary outcomes

  1. Satisfaction of pain control on postoperative day one

    Overall satisfaction of pain control on postoperative day one (binary question - Yes/No)

    Time frame: 1 day

  2. Satisfaction of pain control on postoperative day seven

    Overall satisfaction of pain control on postoperative day seven (binary question - Yes/No)

    Time frame: 7 days

  3. Mobility on postoperative day one

    Satisfaction with mobility on postoperative day one (binary question - Yes/No)

    Time frame: 1 day

  4. Mobility on postoperative day seven

    Satisfaction with mobility on postoperative day seven (binary question - Yes/No)

    Time frame: 7 days

  5. Total opioid consumption on postoperative day one

    Total narcotic consumption by postoperative day one (in morphine milligram equivalent)

    Time frame: 1 day

  6. Total opioid consumption on postoperative day seven

    Total narcotic consumption by postoperative day seven (in morphine milligram equivalent)

    Time frame: 7 days

  7. Opioid related side effects on postoperative day one

    Presence of opioid related side effects such as nausea, vomiting, constipation, dizziness, abdominal distention, and itchiness on postoperative day one (binary question - Yes/No)

    Time frame: 1 day

  8. Opioid related side effects on postoperative day seven

    Presence of opioid related side effects such as nausea, vomiting, constipation, dizziness, abdominal distention, and itchiness on postoperative day seven (binary question - Yes/No)

    Time frame: 7 days

  9. Unplanned calls/visits

    Unplanned visits to the emergency room or clinic and unexpected patient initiated phone call related to pain control postoperatively (binary question - Yes/No)

    Time frame: 7 days

07

Study locations

1 site
08

References and documents

Publications

  • Leaf MC, Wainger J, Frost A, Musselman K, Patzkowsky K, Simpson K, Wu H, Vaidya D, Ma J, AlAshqar A, Wang KC, Borahay MA. Evaluating Routine Opioid Compared With Nonopioid Prescribing After Laparoscopic Hysterectomy: A Randomized Controlled Trial. Obstet Gynecol. 2026 Jul 30. doi: 10.1097/AOG.0000000000006378. Online ahead of print. PubMed 42535875 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Dec 2026, 47 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 47 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2022
First posted
Sep 21, 2022
StartActual
Jan 12, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05548582
Responsible party
Sponsor
First posted
Sep 21, 2022
Start date
Jan 12, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Jan 12, 2026

Study contacts

Mostafa Borahay
principal investigator · Johns Hopkins University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Oxycodone

Start the discussion